Neurodegenerative disorders represent a complex group of conditions that gradually damage the brain and nervous system over time. While these conditions remain incurable, modern medical advances have opened new doors for managing symptoms, slowing disease progression, and improving the lives of millions of people worldwide.

Understanding How Treatment Aims to Help

Treating neurodegenerative disorders focuses on several key goals that work together to help patients maintain the best possible quality of life. The primary aim is to control symptoms that affect daily activities, such as memory loss, movement difficulties, or behavioral changes. Because these conditions develop and progress differently in each person, treatment plans must be carefully tailored to match the specific disease stage and individual patient needs.^[1]

Medical professionals work to slow down the progression of these conditions whenever possible. While we cannot yet reverse the damage that occurs in the brain, slowing the disease gives patients more time to remain independent and engaged with their loved ones. Treatment also addresses the complications that arise from neurodegenerative conditions, such as difficulty swallowing, sleep problems, or mood changes.

Standard treatments approved by medical societies and regulatory bodies form the foundation of care for most patients. These approaches have been studied extensively and shown to provide benefit, even though they cannot cure the underlying disease. At the same time, researchers worldwide are exploring innovative therapies in clinical trials, testing new drugs and treatment methods that might work better or address the root causes of neurodegeneration.^[4]

Established Treatment Approaches for Neurodegenerative Conditions

Current standard treatments for neurodegenerative disorders vary significantly depending on which specific condition a person has. For Alzheimer’s disease, which affects memory and thinking, doctors commonly prescribe medications called cholinesterase inhibitors. These drugs work by increasing levels of a chemical messenger in the brain that helps with memory and judgment. Common examples include donepezil, rivastigmine, and galantamine. These medications cannot stop the disease, but they may help maintain cognitive function for several months to a few years.^[5]

Another class of drugs used for Alzheimer’s disease is called NMDA receptor antagonists, with memantine being the most common example. This medication works differently by regulating the activity of glutamate, another brain chemical involved in learning and memory. It is typically prescribed for moderate to severe stages of the disease and may help slow the decline in daily functioning.

For Parkinson’s disease, which primarily affects movement, the gold standard treatment remains levodopa (also called L-dopa). This medication is converted into dopamine in the brain, replacing the dopamine that is lost as brain cells die. Levodopa significantly improves movement problems such as tremors, stiffness, and slow movements. However, after several years of use, many patients experience complications including involuntary movements and fluctuations in symptom control.^[13]

Other medications used for Parkinson’s disease include dopamine agonists, which mimic the action of dopamine in the brain, and MAO-B inhibitors, which prevent the breakdown of dopamine. In some cases, doctors may recommend deep brain stimulation, a surgical procedure where electrodes are implanted in specific brain areas to help control movement symptoms.

For multiple sclerosis, a demyelinating disease that damages the protective coating around nerve fibers, treatment focuses on modifying the course of the disease and managing relapses. Disease-modifying therapies include injectable medications like interferon beta and glatiramer acetate, as well as oral drugs such as fingolimod and dimethyl fumarate. These medications work by reducing inflammation and slowing damage to the nervous system.^[1]

In amyotrophic lateral sclerosis (ALS), a motor neuron disease, the medication riluzole has been shown to modestly slow disease progression. It works by reducing levels of glutamate, which can be toxic to nerve cells when present in excess. Physical therapy, respiratory support, and nutritional management are equally important components of ALS care.

The duration of these treatments varies by condition and individual response. Many patients with Alzheimer’s disease or Parkinson’s disease remain on their medications for years, with doses adjusted as needed. Treatment for multiple sclerosis often continues indefinitely, as stopping disease-modifying therapies can lead to increased disease activity.

Side effects are an important consideration with all these medications. Cholinesterase inhibitors commonly cause nausea, vomiting, and diarrhea, especially when first starting treatment. Levodopa can cause nausea, dizziness, and confusion, and long-term use may lead to involuntary movements. Disease-modifying therapies for multiple sclerosis can cause flu-like symptoms, liver problems, and changes in immune function. Careful monitoring by healthcare providers helps manage these side effects while maintaining the benefits of treatment.^[10]

Innovative Therapies Being Tested in Clinical Research

The landscape of neurodegenerative disease treatment is rapidly evolving as researchers explore groundbreaking approaches in clinical trials. These studies are testing therapies that target the underlying mechanisms of disease rather than just treating symptoms. Understanding which phase a trial is in helps explain what researchers are learning: Phase I trials test safety and dosing in small groups, Phase II trials evaluate effectiveness and further safety in larger groups, and Phase III trials compare the new treatment with current standard treatments in even larger patient populations.^[4]

One of the most promising areas of research involves gene therapy, which aims to modify genes to slow or stop disease progression. For Alzheimer’s disease, researchers are investigating gene therapy approaches that target the production of proteins like beta-amyloid and tau, which accumulate abnormally in the brains of affected individuals. These therapies use modified viruses as vehicles to deliver therapeutic genes to specific brain regions.

Gene therapy has shown particularly encouraging results for spinal muscular atrophy, a genetic neurodegenerative condition affecting motor neurons. The U.S. FDA has approved therapies that increase levels of the SMN protein, which is deficient in this disease. This success has energized research into similar approaches for other neurodegenerative conditions. Studies are now investigating whether gene therapy techniques could be adapted for Parkinson’s disease and Huntington’s disease.^[12]

Another cutting-edge approach involves immunotherapy, which harnesses the body’s immune system to fight disease. For Alzheimer’s disease, several antibody-based treatments are in late-stage clinical trials. These antibodies are designed to bind to and clear beta-amyloid plaques from the brain. Early results from some trials have shown reduction in amyloid plaques and modest slowing of cognitive decline, though researchers continue to refine these approaches to improve effectiveness and reduce side effects.

Researchers are also exploring stem cell therapies, particularly those using mesenchymal stem cells (MSCs). These cells can be obtained from bone marrow, fat tissue, or other sources and have the ability to reduce inflammation and support the survival of existing neurons. In clinical trials, patients receive stem cells either through injection into the bloodstream or directly into the affected areas of the brain or spinal cord. Studies are investigating this approach for multiple conditions including Parkinson’s disease, ALS, and multiple sclerosis.^[11][17]

Even more innovative are therapies using extracellular vesicles (EVs) derived from stem cells. These are tiny bubble-like structures that cells naturally release to communicate with each other. EVs from mesenchymal stem cells contain proteins, genetic material, and other molecules that can protect neurons and reduce harmful inflammation. This approach may offer advantages over whole cell therapies because EVs are smaller and may cross the blood-brain barrier more easily.

Neurotrophic factors represent another exciting area of investigation. These are naturally occurring proteins that support neuron survival and function. Clinical trials are testing various methods to deliver these factors to the brain, including direct infusion, gene therapy approaches, and modified cells that can produce the factors. Studies are examining whether increasing levels of neurotrophic factors can slow or prevent neuron death in conditions like Parkinson’s disease and ALS.^[13]

Several specific molecules are currently in clinical development. For example, researchers are testing small molecule inhibitors that target specific enzymes involved in the production of toxic proteins. These drugs aim to reduce the accumulation of harmful protein aggregates that damage neurons. Trials are evaluating different formulations and dosing schedules to find the optimal balance between effectiveness and safety.

Many of these clinical trials are being conducted at major medical centers in the United States, Europe, and increasingly in Asia. Patient eligibility varies by trial but typically depends on factors such as disease stage, age, previous treatments, and overall health status. Some trials specifically recruit patients in early disease stages, hoping to slow progression before extensive damage occurs. Others focus on more advanced patients to test whether therapies can still provide benefit.^[13]

One challenge facing all these innovative therapies is crossing the blood-brain barrier, a protective membrane that prevents most substances from entering the brain. Nearly 99% of potential drugs cannot penetrate this barrier effectively. Researchers are developing novel delivery methods, including nanoparticles and modified viruses, specifically designed to overcome this obstacle and deliver therapeutic molecules directly to affected brain regions.^[4]

Early results from some clinical trials have been encouraging. For instance, certain immunotherapy approaches have demonstrated the ability to reduce brain protein deposits and show modest effects on slowing cognitive decline. Gene therapy trials for spinal muscular atrophy have shown dramatic improvements in motor function and survival. Stem cell approaches have shown positive safety profiles and hints of clinical benefit in early-phase studies, though larger trials are needed to confirm effectiveness.

However, it’s important to recognize that many promising treatments fail in later stages of testing. The complexity of the brain and the diversity of neurodegenerative diseases mean that what works in laboratory models doesn’t always translate to human patients. Researchers are working to better understand the mechanisms of these diseases at the molecular level, which will help design more targeted and effective therapies in the future.^[9]

Most common treatment methods

• Pharmacological treatments
  • Cholinesterase inhibitors (donepezil, rivastigmine, galantamine) for Alzheimer’s disease to support memory and thinking
  • NMDA receptor antagonists (memantine) for moderate to severe Alzheimer’s disease
  • Levodopa for Parkinson’s disease to replace lost dopamine and improve movement
  • Dopamine agonists and MAO-B inhibitors for Parkinson’s disease symptom management
  • Disease-modifying therapies for multiple sclerosis including interferon beta and oral medications
  • Riluzole for amyotrophic lateral sclerosis to modestly slow disease progression
• Surgical and device-based interventions
  • Deep brain stimulation for Parkinson’s disease to control movement symptoms through implanted electrodes
• Gene therapy approaches
  • Modified viruses delivering therapeutic genes to increase protein production in spinal muscular atrophy
  • Experimental gene therapies targeting beta-amyloid and tau in Alzheimer’s disease
  • Gene therapy approaches under investigation for Parkinson’s and Huntington’s disease
• Immunotherapy
  • Antibody-based treatments targeting beta-amyloid plaques in Alzheimer’s disease clinical trials
  • Immune-modulating approaches to reduce inflammation and neurodegeneration
• Stem cell and regenerative therapies
  • Mesenchymal stem cell therapies being tested for multiple neurodegenerative conditions
  • Extracellular vesicles derived from stem cells to deliver protective molecules
  • Experimental approaches for Parkinson’s disease, ALS, and multiple sclerosis
• Neurotrophic factor therapies
  • Delivery of naturally occurring proteins that support neuron survival
  • Gene therapy and cellular approaches to increase neurotrophic factor levels
• Supportive and rehabilitation therapies
  • Physical therapy to maintain mobility and strength
  • Speech therapy for swallowing and communication difficulties
  • Occupational therapy to support daily living activities
  • Respiratory support and nutritional management
  • Psychological and psychiatric support for mood and behavioral symptoms